Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2
نویسندگان
چکیده
Title 1 Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, 2 A-790742 3 Authors 4 Tatyana Dekhtyar*, Teresa I. Ng, Liangjun Lu, Sherie Masse, David A. DeGoey, William J. 5 Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Akhteruzzaman Molla 6 Global Pharmaceutical Research and Development, Abbott, Abbott Park, IL 60064, USA 7 Running Title 8 A-790742, a novel HIV-1 protease inhibitor 9 *Corresponding Author and Address for Reprints 10 Tatyana Dekhtyar 11 200 Abbott Park Rd 12 R43H, AP52-N Abbott Park, IL60064 13 T: 847-935-1318 14 F: 847-938-3403 15 [email protected] 16 AC CE PT ED Copyright © 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Antimicrob. Agents Chemother. doi:10.1128/AAC.01132-07 AAC Accepts, published online ahead of print on 22 January 2008
منابع مشابه
Resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach
Human immunodeficiency virus type 1 (HIV-1) protease inhibitors comprise an important class of drugs used in HIV treatments. However, mutations of protease genes accelerated by low fidelity of reverse transcriptase yield drug resistant mutants of reduced affinities for the inhibitors. This problem is considered to be a serious barrier against HIV treatment for the foreseeable future. In this st...
متن کاملEffect of Biomolecular Conformation on Docking Simulation: A Case Study on a Potent HIV-1 Protease Inhibitor
Human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS) is a disease pertained to the human immune system. Given its crucial role in viral replication, HIV-1 protease (HIV-1 PR) is a prime therapeutic target in AIDS therapy. In this regard, the dynamic aspects of ligand-enzyme interactions may indicate an important role of conformational variability in HIV-1 PR in...
متن کاملCharacterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
Inhibitors of the human immunodeficiency virus type 1 protease represent a promising class of antiviral drugs for the treatment of AIDS, and several are now in clinical trials. Here, we report the in vitro selection of viral variants with decreased sensitivity to a C2-symmetric protease inhibitor (A-77003). We show that a single amino acid substitution (Arg to Gln or Lys) at position 8 of the p...
متن کاملSelection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
Inhibitors of the human immunodeficiency virus protease represent a promising new class of antiretroviral drugs for the treatment of AIDS. We now report the in vitro selection of viral variants with decreased sensitivity to a symmetry-based protease inhibitor, ABT-538, currently being tested in clinical trials. Molecular characterization of the variants shows that an isoleucine-to-valine substi...
متن کاملEffect of Biomolecular Conformation on Docking Simulation: A Case Study on a Potent HIV-1 Protease Inhibitor
Human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS) is a disease pertained to the human immune system. Given its crucial role in viral replication, HIV-1 protease (HIV-1 PR) is a prime therapeutic target in AIDS therapy. In this regard, the dynamic aspects of ligand-enzyme interactions may indicate an important role of conformational variability in HIV-1 PR in...
متن کامل